Skip to main content
Merck10-Q: Inventory issue

Lagevrio EUA termination by June 2027 forces Merck to create a product disposition plan

What happened

With the Emergency Use Authorization for its COVID-19 drug ending on a fixed date, Merck faces a hard deadline to manage and dispose of its Lagevrio inventory.

Source

SEC EDGARAug 7, 2026

Quarterly report (Form 10-Q)

Merck 10-Q

Filing excerpt

On June 29, 2026, the Secretary of HHS determined that circumstances no longer exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic and provided advance notice that the declaration supporting the EUA for Lagevrio will terminate, effective June 29, 2027.

sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htmRead the full source

Other signals in this filing (7)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Inventory issue

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
06/30
Filed
Aug 7, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
310158
Accession number
0000310158-26-000212
Filing year
2026
Fiscal year
0
Why it matters
Supply chain tools needed
Signal category
Financial

Topics and mentions

Vendors

  • WuXi Vaccines

Competitors

  • Gilead Sciences
  • Inc.
  • Eisai Co.
  • Ltd.
  • AstraZeneca
  • Bayer AG
  • Daiichi Sankyo
  • Moderna Inc.
  • Bristol Myers Squibb Company
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Regions named

  • U.S.

Competitors named

  • Gilead Sciences, Inc.
  • Eisai Co., Ltd.
  • AstraZeneca
  • Bayer AG
  • Daiichi Sankyo
  • Moderna Inc.
  • Bristol Myers Squibb Company
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Extraction

Confidence
High
Relevance
75%
Sentiment
Negative
Detected
Aug 11, 2026
signal_type
sec-10q
signal_subtype
inventoryIssue

Use this data

Get every 10-Q signal for Merck and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Merck this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/9db940f2-1718-4b5d-8667-0e53fdb8ec88 returns this record as JSON. POST /v1/companies/enrich returns every signal for merck.com.

{
  "signal_id": "9db940f2-1718-4b5d-8667-0e53fdb8ec88",
  "signal_type": "sec-10q",
  "signal_subtype": "inventoryIssue",
  "detected_at": "2026-08-11T08:10:26.837+00:00",
  "company": {
    "name": "Merck",
    "domain": "merck.com"
  },
  "data": {
    "detail": "With the Emergency Use Authorization for its COVID-19 drug ending on a fixed date, Merck faces a hard deadline to manage and dispose of its Lagevrio inventory. This creates an immediate need for logistics, supply chain, and inventory management solutions to handle the wind-down efficiently and avoid write-offs.",
    "summary": "Lagevrio EUA termination by June 2027 forces Merck to create a product disposition plan",
    "excerpts": "On June 29, 2026, the Secretary of HHS determined that circumstances no longer exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic and provided advance notice that the declaration supporting the EUA for Lagevrio will terminate, effective June 29, 2027.",
    "relevance": 0.75,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htm",
    "filing_date": "2026-08-07",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "06/30",
    "sales_relevance": "Supply chain tools needed",
    "signal_category": "financial",
    "regions_mentioned": [
      "U.S."
    ],
    "vendors_mentioned": [
      "WuXi Vaccines"
    ],
    "competitors_mentioned": [
      "Gilead Sciences, Inc.",
      "Eisai Co., Ltd.",
      "AstraZeneca",
      "Bayer AG",
      "Daiichi Sankyo",
      "Moderna Inc.",
      "Bristol Myers Squibb Company",
      "Jiangsu Hengrui Pharmaceuticals Co. Ltd."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.